Please Wait

Applying Filters...

Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

Data Compilation
#PharmaFlow

Pipeline Prospector October 2025: Novartis to buy Avidity for US$ 12 bn; FDA approves Bayer’s med to treat hot flashes

Stock Recap
#PipelineProspector

Ipratropium Bromide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 9 USDMF, 8 CEP/COS, 1 JDMF, 5 EU WC, 9 KDMF, 14 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

36 Drugs in Development

36 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

248 FDF Dossiers, 45 FDA Orange Book, 140 Europe, 17 Canada, 4 Australia, 24 South Africa, 18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SPRAY, METERED;NASAL - 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 5 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

6 Parenteral, 2 Solubilizers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 16 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 49 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

11 APIs, 6 FDF Dossiers, 1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

5 US Patents, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM, 11 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
31/10/2025	Vamsi Labs	India	VAMSI LABS LTD	40419	IPRATROPIUM BROMIDE-EP	2024-08-28	Active	II	N/A
31/10/2025	Aarti Pharmalabs	India	AARTI PHARMALABS LTD	21179	IPRATROPIUM BROMIDE	2007-12-15	Active	II	N/A

Contact us
to update this info

Ipratropium Bromide

Ipratropium Bromide

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers

9 USDMF

8 CEP/COS

1 JDMF

5 EU WC

9 KDMF

14 NDC API

20 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

36 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

248 FDF Dossiers

45 FDA Orange Book

140 Europe

17 Canada

4 Australia

24 South Africa

18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SPRAY, METERED;NASAL - 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INHALATION - EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma

5 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

6 Parenteral

2 Solubilizers

1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

16 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions

49 Regulatory FDF Prices

1 Annual Reports

MARKET PLACE

11 APIs

6 FDF Dossiers

1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

5 US Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM

11 Others

Filters

SPRAY, METERED;NASAL - 0.021MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SPRAY, METERED;NASAL - 0.042MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INHALATION - EQ 0.083% BASE;0.017% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons